| Application no. and date | 23176968.8 (espacenet) (Federated) (European Patent Register), 20190604 | | Patent/reg. no. and date | DK/EP 4249069, 20251119 | | Publication date | 20230927 | | Priority no. and date | US 201862681722 P, 20180607, US 201862754651 P, 20181102, US 201962796133 P, 20190124, US 201962841882 P, 20190502 | | EP pub. no. and date |
EP 4249069 20230927 | | Effective date | | | Applicant/owner | Pfizer Inc., 66 Hudson Boulevard East
New York, NY 10001-2192, US | | Applicant ref. no. | V499906DK00 | | Inventor | HUSSEY, James Joseph,
Sandwich, CT13 9NJ, GB,
BRIGHT, Andrew Gilbert,
Sandwich, CT13 9NJ, GB | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 31/5377 (2006.01) , A61K 47/12 (2006.01) , A61K 47/40 (2006.01) , A61K 9/00 (2006.01) , A61K 9/08 (2006.01) , A61K 9/19 (2006.01) , A61P 35/00 (2006.01) | | Title | Vandig formulering omfattende 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
